Marktanalyse - Canavan Disease - Pipeline Review, H2 2016

Global Markets Direct
12.2016
29 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Canavan Disease - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H2 2016, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape.

Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene which directs the production of the enzyme aspartoacylase (ASPA) allows the buildup of N-acetylaspartic acid (NAA) in the brain. The buildup of NAA causes damage to myelin. Symptoms include lack of motor development, feeding difficulties, abnormal muscle tone, and an abnormally large, poorly controlled head, paralysis, blindness, or hearing loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Canavan Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Canavan Disease.

Canavan Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Canavan Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Canavan Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Canavan Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Canavan Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Canavan Disease (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Canavan Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Canavan Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Canavan Disease Overview 5

Therapeutics Development 6

Pipeline Products for Canavan Disease - Overview 6

Pipeline Products for Canavan Disease - Comparative Analysis 7

Canavan Disease - Therapeutics under Development by Companies 8

Canavan Disease - Therapeutics under Investigation by Universities/Institutes 9

Canavan Disease - Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Canavan Disease - Products under Development by Companies 12

Canavan Disease - Products under Investigation by Universities/Institutes 13

Canavan Disease - Companies Involved in Therapeutics Development 14

Turing Pharmaceuticals AG 14

Canavan Disease - Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Target 16

Assessment by Mechanism of Action 17

Assessment by Molecule Type 19

Drug Profiles 21

Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Gene therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Recombinant Enzyme to Replace Aspartoacylase for Canavan Disease - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

TUR-007 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Canavan Disease - Dormant Projects 26

Canavan Disease - Discontinued Products 27

Appendix 28

Methodology 28

Coverage 28

Secondary Research 28

Primary Research 28

Expert Panel Validation 28

Contact Us 28

Disclaimer 29





List of Tables

Number of Products under Development for Canavan Disease, H2 2016 6

Number of Products under Development for Canavan Disease - Comparative Analysis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Number of Products under Investigation by Universities/Institutes, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Canavan Disease - Pipeline by Turing Pharmaceuticals AG, H2 2016 14

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Stage and Target, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Canavan Disease - Dormant Projects, H2 2016 26

Canavan Disease - Discontinued Products, H2 2016 27





List of Figures

Number of Products under Development for Canavan Disease, H2 2016 6

Number of Products under Development for Canavan Disease - Comparative Analysis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Stage and Targets, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Types, H2 2016 19

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus